17 Sep Does PCSK9 Genetic Variation Help Predict Risk of Sepsis?
Posted at 11:24h
in Author Interviews, Critical Care - Intensive Care - ICUs, Genetic Research, Infections, JAMA
MedicalResearch.com Interview with:
[caption id="attachment_51330" align="alignleft" width="142"]
Dr. QiPing Feng[/caption]
QiPing Feng, PhD
Division of Clinical Pharmacology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee
MedicalResearch.com: What is the background for this study?
Response: Sepsis is one of the leading causes of hospital mortality. Yet, there are no specific effective treatments for it. Recent information suggests that drugs that inhibit proprotein convertase subtilisin kexin type 9 (PCSK9) could have potential as a new treatment for sepsis.
We used a genetic approach to test if variation in PCSK9 affected the risk of sepsis.
In patients admitted to hospital with infection, neither variants in the PCSK9 gene nor predicted expression of PCSK9 were associated with risk of sepsis or poorer outcomes after sepsis.


